Literature DB >> 12615872

Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.

D Van Kerkhoven1, W E Peetermans, L Verbist, J Verhaegen.   

Abstract

The incidence of penicillin- and erythromycin-resistant strains of Streptococcus pneumoniae has increased considerably in Belgium. The medical charts of all patients with pneumococcal bacteraemia who were admitted to hospital over a period of 3 years (n = 136) were reviewed to identify treatment failure of outpatient antibiotic therapy. Twelve patients had received antibiotics for at least 48 h prior to admission. Four treatment failures received clarithromycin as pre-hospitalization therapy, and S. pneumoniae from all four patients were highly resistant to macrolides. Five patients failed on co-amoxiclav, whereas their S. pneumoniae were susceptible to penicillin and amoxicillin. This observation suggests that macrolide resistance is clinically relevant and leads to treatment failure, whereas suboptimal dosing may explain breakthrough pneumococcal bacteraemia in beta-lactam-treated patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615872     DOI: 10.1093/jac/dkg116

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 2.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

Review 3.  Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.

Authors:  Stephen Brunton; Paul Iannini
Journal:  MedGenMed       Date:  2005-12-07

4.  Bacteremic pneumococcal pneumonia associated with macrolide failure.

Authors:  J Dylewski; R Davidson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

Review 5.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

6.  Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae.

Authors:  Cheol-In Kang; Jin Yang Baek; Kyeongman Jeon; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

7.  Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.

Authors:  David J Farrell; Thomas M File; Stephen G Jenkins
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  What Is the Clinical Impact of Macrolide Resistance?

Authors:  John R. Lonks
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

10.  Increase in pneumococcus macrolide resistance, United States.

Authors:  Stephen G Jenkins; David J Farrell
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.